|
Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Ipsen; Novartis |
Consulting or Advisory Role - Celgene; Ipsen; Novartis; Pfizer |
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
|
|
|
|
|
Susan W. Pitman Lowenthal |
|
|
|
Consulting or Advisory Role - Alnylam; Astellas Pharma; Hydra Biosciences; ION Pharma; Ipsen; Merck; Pfizer |
|
Research Funding - Matrix Biomed (Inst); Nestle health science (Inst); Novo Nordisk (Inst); VeroScience (Inst); ViroMed (Inst) |
|
|
Stock and Other Ownership Interests - Seagen (I) |
Honoraria - Merck, Genentech, Ipsen |
Consulting or Advisory Role - Celgene; ipsen |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Ipsen (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmaceutical Research Associates (Inst); Polaris (Inst); Sun Pharma (Inst); XBiotech (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Merck |
|
|
Consulting or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer |
Research Funding - Ipsen (Inst); Novartis (Inst) |